by , Rita F. Redberg, Emelia J. Benjamin, Vera Bittner, Lynne T

Slides:

Advertisements

Similar presentations

Summary Prepared by Melvyn Rubenfire, MD

Advertisements

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care

Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

o Number one killer in United States o Killed > 1 million men and women in 2010 o Most common form of heart disease is coronary heart disease, which often.

Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?

{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.

Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.

Global impact of ischemic heart disease World Heart Federation, 2011.

Estimate of Certainty (Precision) of Treatment Effect Level of evidence of B or C does not imply that recommendation is weak. LEVEL A Multiple populations.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.

10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Application of the Screening for Heart Attack Prevention.

2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the.

YOUR HEALTH SCREENING RESULTS

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2009 American Medical Association. All rights reserved.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Major recommendation for statin therapy for ASCVD prevention

Alina M. Allen MD, Patrick S. Kamath MD, Joseph J. Larson,

Safi U. Khan MD; John Pamula MD

Copyright © 2001 American Medical Association. All rights reserved.

Cholesterol practice questions

HDL cholesterol and cardiovascular risk Epidemiological evidence

Copyright © 2012 American Medical Association. All rights reserved.

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.

by Salim Yusuf, and Sonia Anand

HDL cholesterol and cardiovascular risk

Association of Lipids With Incident Heart Failure Among Adults With and Without Diabetes MellitusClinical Perspective by Imo A. Ebong, David C. Goff, Carlos.

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Prehypertension, Diabetes, and Cardiovascular Disease Risk in a Population-Based Sample by Ying Zhang, Elisa T. Lee, Richard B. Devereux, Jeunliang Yeh,

Body Mass Index, Sex, and Cardiovascular Disease Risk Factors Among Hispanic/Latino Adults: Hispanic Community Health Study/Study of Latinos by Robert.

Behavior and Biology: The Basic Sciences for AHA Action

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Body Mass Index and Heart Failure Among Patients With Type 2 Diabetes MellitusCLINICAL PERSPECTIVE by Weiqin Li, Peter T. Katzmarzyk, Ronald Horswell,

by John T. Wilkins, Hongyan Ning, Neil J. Stone, Michael H

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Neil J. Stone et al. JACC 2014;63:

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Machine Learning Vulnerable Patient Project

Baseline characteristics of HPS participants by prior diabetes

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Case 1: A 73-year-old white female with carotid disease

Type 2 diabetes: Overlap of clinical conditions

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

by Peter Ueda, Thomas Wai-Chun Lung, Philip Clarke, and Goodarz Danaei

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Primary and Secondary Prevention of Cardiovascular Disease

by Peter Ueda, Thomas Wai-Chun Lung, Philip Clarke, and Goodarz Danaei

Description of studies for pooled analyses

Rational Order of Laboratory Tests in Cardiovascular Diseases

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

O.L.Reuchlin gebruik van CT binnen de cardiogie

Contemporary Evidence-Based Guidelines

Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention Abdallah Al-Salameh, MD, Philippe Chanson,

Goals & Guidelines A summary of international guidelines for CHD

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Baseline Characteristics of the Subjects*

Cardiovascular Disease in Women Module III: Risk Assessment Tool

Cardiovascular Disease in Women Module IX: Presentation Resources and Internet Resources This slide set was updated April 2008.

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

AHA/ACCF 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults by , Rita F. Redberg, Emelia J. Benjamin, Vera Bittner, Lynne T. Braun, David C. Goff, Stephen Havas, Darwin R. Labarthe, Marian C. Limacher, Donald M. Lloyd-Jones, Samia Mora, Thomas A. Pearson, Martha J. Radford, Gerald W. Smetana, John A. Spertus, and Erica W. Swegler Circulation Volume 120(13):1296-1336 September 29, 2009 Copyright © American Heart Association, Inc. All rights reserved.

Table 2. Applying Classification of Recommendations and Level of Evidence*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. Table 2. Applying Classification of Recommendations and Level of Evidence*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.†In 2003, the ACCF/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline recommendations have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

Table 3. AHA/ACCF Primary Prevention of Cardiovascular Disease Performance Measurement Set: Dimension of Care Measures Matrix. Table 3. AHA/ACCF Primary Prevention of Cardiovascular Disease Performance Measurement Set: Dimension of Care Measures Matrix WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

CHD score sheet for men using total cholesterol or LDL-C categories. CHD score sheet for men using total cholesterol or LDL-C categories. Uses age, total cholesterol (or LDL-C), HDL-C, blood pressure, diabetes, and smoking. Estimates risk for CHD over a period of 10 years based on Framingham experience in men 30 to 74 years of age at baseline. Average risk estimates are based on typical Framingham subjects, and estimates of idealized risk are based on optimal blood pressure, total cholesterol 160 to 199 mg/dL (or LDL-C 100 to 129 mg/dL), HDL-C of 45 mg/dL in men, no diabetes, and no smoking. Use of the LDL-C categories is appropriate when fasting LDL-C measurements are available. Risk estimates were derived from the experience of the Framingham Heart Study, a predominantly white population in Massachusetts. CHD indicates cardiovascular heart diease; chol, cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and Pts, patients. Adapted from Wilson et al,50 with permission from Lippincott Williams & Wilkins. Copyright 1998, American Heart Association. *Hard CHD events exclude angina pectoris. **Low risk was calculated for a person the same age, optimal blood pressure, LDL-C 100–129 mg/dL or cholesterol 160–199 mg/dL. HDL-C 45 mg/dL for men or 55 mg/dL for women, nonsmoker, no diabetes. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

Reprinted from NIH Publication No. 00-4084.103. WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.

BMI indicates body mass index. BMI indicates body mass index. Adapted from: NIH Publication No. 00-4084.103 WRITING COMMITTEE MEMBERS et al. Circulation. 2009;120:1296-1336 Copyright © American Heart Association, Inc. All rights reserved.